JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present at the 2018 BIO International Convention at 2:00 PM ET on Wednesday, June 6, 2018. The conference will be held at the Boston Convention and Exhibition Center.
Mr. Pham will provide a corporate overview and discuss the company’s late-stage product pipeline, including tecarfarin, Espero’s lead product candidate, and budiodarone, an anti-arrhythmic product candidate being developed for the treatment of refractory atrial fibrillation. Tecarfarin is a reversible, broad-use anticoagulant product candidate being developed for patients with difficulty controlling anticoagulation with warfarin or that cannot be treated with non-Vitamin K oral anticoagulants (NOACs), including patients with prosthetic heart valves, recurrent deep vein thrombosis or patients with chronic kidney disease, which complicates anticoagulant therapy. Budiodarone is being developed to significantly reduce atrial fibrillation burden with a predictable dose response and rapid metabolic clearance. Budiodarone is being further evaluated as a novel anti-arrhythmic agent for the treatment of refractory atrial fibrillation.
About Espero BioPharma, Inc.
Espero BioPharma, Inc. is a platform biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases. Additional information about Espero BioPharma is available at www.esperobio.com.
IR Contact
David Carey
Lazar Partners Ltd.
T: (212) 867-1768
dcarey@lazarpartners.com
PR Contact
Tom Vickery
Lazar Partners Ltd.
T: (646) 871-8482
tvickery@lazarpartners.com
